NCT02242942 2025-11-06Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaHoffmann-La RochePhase 3 Completed445 enrolled 22 charts 1 FDA
NCT02475681 2025-08-27ElevateTNAcerta Pharma BVPhase 3 Active not recruiting535 enrolled 19 charts 1 FDA
NCT02257567 2022-11-14A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaHoffmann-La RochePhase 1/2 Completed331 enrolled 81 charts 1 FDA